Protocols - Hemorio

More documents

Recommendations

Info

MAJOR AND INTERMIDIATE THALASSEMIA DIAGNOSTIC EXAMS - Peripheral blood study + complete red blood cell (VCM e CHM) + retyculocytes - Hb A2 dosage and fetal - Osmotic fragile curve - Family Study (parent and siblings) MAJOR THALASSEMIAX INTERMEDIATE THALASSEMIA - MAJOR – Hb maintenance < 7g/dL - INTERMEDIATE - Hb maintenance > 8g/dL PERIODIC CONTROL DIAGNOSE QUARTER SEMESTRAL ANNUAL - Conduct to Interdisciplinary Group of Thalassemia treatment - Immunhematologic study (phenotype) - Serology (hepatitis A,B,C, HIV, HTLV, CMV) - Vaccination for hepatitis B (depend on serology) - PPD (for non reactors) - Medical consultation - ferrokinetics (ferritine, TIBC) - Glucose, urea, creatinine, LDH - TGO, TGP, FAL, gamma-GT Cardiologic Evaluation - Echocardiogram - ECG (12-lead) - Chest x-ray Serologic Evaluation - Hepatitis: A (anti HAV – IgG) / B (HBSAg, Anti HBS and anti HBC IgG / C (Anti HCV) - Retrovirus (Anti HIV, Anti HTLV) Evaluation of growth curve (compare to parent and siblings height) - Graphics Age X Weight X Height - Accurate measurement of height (stand and sit positions) Thyroid Evaluation (as of 12 years) - Free TRH, T4 and TSH Parathyroid Evaluation (as of 16 years) - Calcium - Phosphate serum - PTH Other hormonal evaluations - LH / FSH - Testosterone - Estradiol - cortisol on morning fasting Tanner staging of puberty Ophthalmological Evaluation - Campimeter and Fundus of eyes Audiometric Evaluation - Oral glucose tolerance test - Fist and hand x-rays - Densitometry or bone x-ray - Cholesterol total, HDL and triglyceride - RNM T2* (hepatic and cardiac evaluation) 40
- Abdominal US TREATAMENT HYPERTRANSFUSION: See HEMOTERAPIC PROTOCOLS INDICATIONS: - Major Thalassemia – all cases - Intermediate Thalassemia – with facial changes, growth retard, pathologic fractures and/or extramedullar hematopoiesis HYDROXYUREA INDICATIONS: Intermediate Thalassemia Inclusion criteria, posology, monitoring, precautions and care are identical from HU protocol used in Falciform Disease. 41
Page 2 and 3: PROTOCOLS INSTITUTE OF HAEMATOLOGY
Page 4 and 5: COORDINATION AND REVISION Clarisse
Page 6 and 7: SUMMARY: PART I - CLINICAL PROTOCOL
Page 8 and 9: 1.INICIAL CLINICAL EVALUATION SICKL
Page 10 and 11: TREATMENTO AND IN ADULTS AT ANY AGE
Page 12 and 13: SPLENECTOMY - INDICATIONS: (1) CHIL
Page 14 and 15: OUTPATIENT TREATMENT: It is based o
Page 16 and 17: ASPIRIN AND NSAID PARACETAMOL OPIOI
Page 18 and 19: CONDUCTION: - Hospitalization - Com
Page 20 and 21: ONE, TWO-DIMENSIONAL DOPPLER ECHOCA
Page 22 and 23: Hemianopsia Homonymous deficit of v
Page 24 and 25: TREATMENT OF CONVULSIVE EPISODES -
Page 26 and 27: INITIAL ATTENDANCE TO PREGNANT WOME
Page 28 and 29: - It may occurs acute thoracic synd
Page 30 and 31: 3 Diet with potassium restriction 4
Page 32 and 33: MICROALBUMINURIA Screening Patients
Page 34 and 35: RECURRENCE OF PRIAPISM: - Pain Trea
Page 36 and 37: SPECIAL CARES DEFERASIROX - The use
Page 38 and 39: TREATAMENT: DRUG Hydroxiurea (hard
Page 42 and 43: HEREDIRATY SPHEROCYTOSIS CLINICAL E
Page 44 and 45: G6PD DEFICIENCY INITIAL EVALUATION
Page 46 and 47: LABS EXAMS TO DIAGNOSE APLASTIC ANE
Page 48 and 49: SELFIMMUNE HEMOLYTIC ANEMIA CONCEPT
Page 50 and 51: 2. Splenectomy: Vaccinate 14 days b
Page 52 and 53: IMMUNE THROMBOCYTOPENIC PURPURA LAB
Page 54 and 55: THROMBOTIC THROMBOCYTOPENIC PURPURA
Page 56 and 57: HEMORRHAGIC SYNDROME INTRODUCTION H
Page 58 and 59: MULTIDISCIPLINARY FOLLOW-UP OF HEMO
Page 60 and 61: LYOPHILIZED CONCENTRATES: They are
Page 62 and 63: TABLE 2: REPLACEMENT THERAPY TO PER
Page 64 and 65: CONDUCTION IN CONFIRMED INTRACRANIA
Page 66 and 67: Severe CET with neurological change
Page 68 and 69: PHARMACOKINETICS OF CLOTTING FACTOR
Page 70 and 71: INHIBITORS CLASSIFICATION The inhib
Page 72 and 73: - Extended surgeries require increa
Page 74 and 75: CLINICAL DIAGNOSIS: According to In
Page 76 and 77: DDAVP TEST The “test dose” must
Page 78 and 79: TREATMENT OF BLEEDING SITUATIONS SI
Page 80 and 81: TABLE 6 - REPLACEMENT THERAPY IN LE
Page 82 and 83: • Primary prophylaxis: controvers
Page 84 and 85: CLINICAL AND LABORATORIAL FOLLOW-UP
Page 86 and 87: MYELODISPLASIC SYNDROME LABORATORIA
Page 88 and 89: If EPO < 500 mU/ml : EPO (8000U 3x/
Page 90 and 91:
ACUTE MYELOID LEUKEMIA LABORATORIAL
Page 92 and 93:
LMA LMA M3 - non-M3 LMA Protocol LM
Page 94 and 95:
Key: Volunteer to aggressive treatm
Page 96 and 97:
Acute Promyelocytic Leukemia Transf
Page 98 and 99:
BMP LMA IN CHILDREN AND TEENAGERS
Page 100 and 101:
Ara-c dose reduction by age: Age in
Page 102 and 103:
ATRA RECOMMENDATION: ATRA is starte
Page 104 and 105:
- venous hydration - leukapheresis
Page 106 and 107:
POLYCYTHEMIA VERA LABORATORIAL TEST
Page 108 and 109:
TREATMENT - 2nd LINE - Indicated fo
Page 110 and 111:
ACUTE LYMPHOID LEUKEMIA LABORATORIA
Page 112 and 113:
RE-INDUCTION Phase I (weeks 1-4) -
Page 114 and 115:
Cycles 2, 4, 6, 8 - Methotrexate 20
Page 116 and 117:
PHASE 2 Infusion CPM in 1 hour 1000
Page 118 and 119:
CURATIVE RADIOTHERAPY of CNS < 1 ye
Page 120 and 121:
CHRONIC LYMPHOCYTIC LEUKEMIA LABORA
Page 122 and 123:
fludarabine 25 mg/m VENOUS 2 D1-D3
Page 124 and 125:
TRICHOLEUKEMIA LABORATORIAL TESTS -
Page 126 and 127:
- age >45 years old - leukocytosis
Page 128 and 129:
- Leukemia / T-Cell Lymphoma in Adu
Page 130 and 131:
INDICATIONS FOR THE TREATMENT: Symp
Page 132 and 133:
1 st line Chemotherapy R- CHOP (21
Page 134 and 135:
CODOX- M/IVAC Cycles 1 and 3 Cyclop
Page 136 and 137:
BLOCK A DEXA VO/IV 10 mg /m2 in 3 d
Page 138 and 139:
- Surgical treatment is only indica
Page 140 and 141:
LEUKEMIA / T-CELLS LYMPHOMA OF THE
Page 142 and 143:
HN2 or PUVA (similar to the located
Page 144 and 145:
MULTIPLE MYELOMA LABORATORIAL TESTS
Page 146 and 147:
RESPONSE CRITERIA Full Response Abs
Page 148 and 149:
WALDENSTRON MACROGLOBULINEMIA LABOR
Page 150 and 151:
− If HLA-identical related donor
Page 152 and 153:
TREATMENT PROTOCOL - ACUTE MYELOID
Page 154 and 155:
TREATMENT PROTOCOL - MULTIPLE MYELO
Page 156 and 157:
Post-autologous transplantation pro
Page 158 and 159:
PART II - TRANSFUSIONAL PROTOCOLS A
Page 160 and 161:
PRESERVATION AND CONSERVATION: The
Page 162 and 163:
TRANSFUSION OF RED BLOOD CELLS, PLA
Page 164 and 165:
FORMAL CONTRAINDICATIONS TO THE PLA
Page 166 and 167:
1 - TRANSFUSION OF FROZEN FRESH PLA
Page 168 and 169:
COMMUNICATION FORM OF CRYOPRECIPITA
Page 170 and 171:
Volume to be = changed (*) VOLEMIA
Page 172 and 173:
HEMOTHERAPIC PROTOCOL TO FALCIFORM
Page 174 and 175:
5 - TRANSFUSIONAL CONDUCT AT THE SE
Page 176 and 177:
CML - Subjects with symptoms relate
Page 178 and 179:
- Aplastic anemia bearers - HIV pos
Page 180 and 181:
Severe reaction: anaphylactic shock
Page 182 and 183:
- Heart monitoring - Prescribe Furo
Page 184 and 185:
CARES AT THE PLATELETS CONCENTRATE
Page 186 and 187:
ATTACHMENT I - HEMATOLOGICAL CLINIC
Page 188 and 189:
INFECTIOUS SPLENO MEGALIES IMMUNO L
Page 190 and 191:
INVESTIGATION OF HEMORRHAGIC SYNDRO
Page 192 and 193:
INVESTIGATION OF POLYGLOBULIAS: POL
Page 194 and 195:
ATTACHMENT III - HEMATOLOGY SPECIAL
Page 196 and 197:
IMMUNOPHENOTYPE PROFILE OF THE ACUT
Page 198 and 199:
ATTACHMENT IV - PAIN APPROACH ROUTI
Page 200 and 201:
If it is prescribed for more than 1
Page 202 and 203:
HOW TO PRESCRIBE OPIOID: SPECIAL CA
Page 204 and 205:
SPECIFICITIES OF EACH OPIATE (cont
Page 206 and 207:
METHADONE Intravenous (*) Oral path
Page 208 and 209:
Psychic Dependence or “addiction
Page 210 and 211:
CROSS TOLERANCE - The subject must
Page 212 and 213:
ATTACHMENT V - CHEMOTHERAPY SUBJECT
Page 214 and 215:
ATTACHMENT VII - IRON CHELATION GEN
Page 216 and 217:
10. G N N - DFP DFP-100 mg/kg/day d
Page 218 and 219:
ATTACHMENT VIII - SEDATION IN CHILD
Page 220 and 221:
224 NOTES _________________________
Page 222 and 223:
224 NOTES _________________________
Page 224:
Expresso Gráfica e Editora Ltda-me
show all

Protocols - Hemorio

Create successful ePaper yourself

Delete template?

Save as template?